Eupraxia Pharmaceuticals is trading 5.94% up at $8.02 in pre-market; no new company-specific announcement explains the October 9 move.
- The October 8 close was $7.57. The latest major company news was September 30 clinical-trial data; interim Phase 2b data are expected in December.
- Broader markets also point higher pre-market as oil prices eased and concerns about geopolitical escalation and AI investment moderated. This may provide a supportive backdrop, but available evidence does not establish a direct cause for the stock’s gain.